Toll Free: 1-888-928-9744
Published: Mar, 2014 | Pages:
41 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Biotest AG - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Biotest AG - Product Pipeline Review - 2014', provides an overview of the Biotest AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Biotest AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Biotest AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Biotest AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Biotest AG's pipeline products Reasons to buy - Evaluate Biotest AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Biotest AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Biotest AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Biotest AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biotest AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Biotest AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Biotest AG Snapshot 5 Biotest AG Overview 5 Key Information 5 Key Facts 5 Biotest AG - Research and Development Overview 6 Key Therapeutic Areas 6 Biotest AG - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Biotest AG - Pipeline Products Glance 13 Biotest AG - Late Stage Pipeline Products 13 Phase III Products/Combination Treatment Modalities 13 Biotest AG - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Biotest AG - Early Stage Pipeline Products 16 IND/CTA Filed Products/Combination Treatment Modalities 16 Preclinical Products/Combination Treatment Modalities 17 Biotest AG - Drug Profiles 18 hepatitis C immune globulin (human) 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 BT-086 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 indatuximab ravtansine 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 tregalizumab 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 fibrinogen concentrate (human) 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 BT-063 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Biotest AG - Pipeline Analysis 27 Biotest AG - Pipeline Products by Target 27 Biotest AG - Pipeline Products by Route of Administration 28 Biotest AG - Pipeline Products by Molecule Type 29 Biotest AG - Pipeline Products by Mechanism of Action 30 Biotest AG - Recent Pipeline Updates 31 Biotest AG - Dormant Projects 34 Biotest AG - Company Statement 35 Biotest AG - Locations And Subsidiaries 37 Head Office 37 Other Locations & Subsidiaries 37 Biotest AG - Key Manufacturing Facilities 39 Appendix 40 Methodology 40 Coverage 40 Secondary Research 40 Primary Research 40 Expert Panel Validation 40 Contact Us 41 Disclaimer 41
List of Tables Biotest AG, Key Information 5 Biotest AG, Key Facts 5 Biotest AG - Pipeline by Indication, 2014 8 Biotest AG - Pipeline by Stage of Development, 2014 9 Biotest AG - Monotherapy Products in Pipeline, 2014 10 Biotest AG - Partnered Products in Pipeline, 2014 11 Biotest AG - Partnered Products/ Combination Treatment Modalities, 2014 12 Biotest AG - Phase III, 2014 13 Biotest AG - Phase II, 2014 14 Biotest AG - Phase I, 2014 15 Biotest AG - IND/CTA Filed, 2014 16 Biotest AG - Preclinical, 2014 17 Biotest AG - Pipeline by Target, 2014 27 Biotest AG - Pipeline by Route of Administration, 2014 28 Biotest AG - Pipeline by Molecule Type, 2014 29 Biotest AG - Pipeline Products by Mechanism of Action, 2014 30 Biotest AG - Recent Pipeline Updates, 2014 31 Biotest AG - Dormant Developmental Projects,2014 34 Biotest AG, Subsidiaries 37 Biotest AG, Key Manufacturing Facilities 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.